BURLINGTON, Mass., Aug. 11, 2015 /PRNewswire/ -- Decision Resources Group finds that the cardiac assist device market will experience moderate growth through 2023. The overall market will be driven primarily by the expanding use of ventricular assist devices (VADs), which are being increasingly adopted with improving physician awareness and training, as well as, expanding indications for use. The total artificial heart (TAH) market will also expand rapidly because these products are one of the only options for bridging patients with biventricular failure to transplantation. The intra-aortic balloon pump market will be the only one to contract. While these devices continue to be used because of physician familiarity, their use will ultimately decline due to a lack of clinical evidence supporting their use and competition from alternative options, including extracorporeal membrane oxygenation.
Other key findings from Decision Resources Group's Medtech 360 European Markets for Cardiac Assist Devices 2015 report:
- The lack of full reimbursement remains a limiter of the VAD market in Europe. For example, in France, not all CE mark-approved VADs receive reimbursement and, in the UK, NICE guidelines outline that durable VADs can only be implanted in patients who are eligible for and awaiting a heart transplant, restricting the number of patients who are treated using these devices. Because of the high price of VADs, especially durable VADs, reimbursement is an important factor for adoption of these devices.
- Device innovation will remain critical to the growth of the cardiac assist device market. New devices will expand the patient population by increasing the indications for which devices can be used. Some devices in development will also be more appealing to patients. For example, fully implantable VADs, which are currently under development, will take away the need for patients to carry around the portable drivers that are needed to power current-generation VADs. Eliminating the need for an external driver means a higher quality of life for patients, and therefore fewer reservations when considering VAD implantation as a treatment option.
Comments from Decision Resources Group Senior Analyst Sivani Paskaradevan:
- "There are very few options for individuals suffering from advanced heart failure. Once medications are no longer effective, cardiac assist devices are the primary treatment option if a donor heart is not available. Across Europe, the availability of donor hearts is declining, which means that the need for effective devices is increasing."
- "The VAD market has, to date, consisted of small manufacturers that offer only these niche devices. The announcement that St. Jude Medical will acquire Thoratec, the global leader in the VAD market, brings in the first multinational corporation (MNC). This will increase the competition in the VAD market and will likely draw in other MNCs so that they can better compete with St. Jude Medical's full line of heart failure devices, including VADs."
- Sivani Paskaradevan has written a blog on the subject, which can be found here.
For more information on purchasing this report, please email firstname.lastname@example.org.
About Decision Resources Group
Decision Resources Group offers best-in-class, high-value data, analytics and insights products and services to the healthcare industry, delivered by more than 700 employees across 15 global locations. DRG companies provide the pharmaceutical, biotech, medical device, financial services and payer industries with the tools, insights and advice they need to compete and thrive in an increasingly complex and value-based marketplace. DecisionResourcesGroup.com.
SOURCE Decision Resources Group